Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide

Melissa Works, Neha Soni, Collin Hauskins, Catherine Sierra, Alex Baturevych, Jon C. Jones, Wendy Curtis, Patrick Carlson, Timothy G. Johnstone, David Kugler, Ronald J. Hause, Yue Jiang, Lindsey Wimberly, Christopher R. Clouser, Heidi K. Jessup, Blythe Sather, Ruth A. Salmon and Michael O. Ports
Melissa Works
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Melissa.works@junotherapeutics.com
Neha Soni
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Collin Hauskins
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Sierra
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Baturevych
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jon C. Jones
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Curtis
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wendy Curtis
Patrick Carlson
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy G. Johnstone
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Kugler
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Kugler
Ronald J. Hause
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ronald J. Hause
Yue Jiang
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsey Wimberly
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher R. Clouser
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heidi K. Jessup
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Blythe Sather
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth A. Salmon
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael O. Ports
Juno Therapeutics, A Celgene Company, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-18-1146 Published December 2019
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Anti-BCMA CAR T cytolytic activity and cytokine production increased with lenalidomide in a concentration-dependent manner. Anti-BCMA CAR T materials from 3 healthy donors and 1 patient donor were assessed for cytokine production using 2 multiple myeloma cell lines. Cytolytic activity (A and C) and cytokine production were measured after 24 hours (B and D) against OPM-2 (A and B) and RPMI-8226 (C and D). Cultures were incubated at a ratio of 0.3:1 (effector to target) for cytolytic activity and 1:1 for cytokine production. Data were normalized to DMSO vehicle control; error bars, SEM. For all functional assessments, dose response modeling indicated a significant effect for lenalidomide for each donor and across all donors (P < 0.001), except healthy donors for RPMI-8226 cytolytic assay. *, P < 0.05 for lenalidomide across each donor.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Anti-BCMA CAR T cytokine production was increased by lenalidomide (Len) within 24 hours and across a range of stimulation intensities. Analysis of CD25 and intracellular cytokine levels (left, white bars indicate baseline effects of bead stimulation) for healthy CAR T donors after 24 hours of BCMA bead stimulation (gated on transduced live CD3+ CAR+) for CD4+ (A) and CD8+ (B) subsets. Gray bars demonstrate relative change for (Len) compared with vehicle alone. C and D, Analysis of effector cytokine production following CAR-specific stimulation on 50 μg BCMA and 50 μg PD-L1 beads for 24 hours in the presence of 1 μmol/L Len. *, P < 0.05 effect of Len for each stimulation condition.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Anti-BCMA CAR T cell count, cytokine production, and activation were increased by lenalidomide after repeated stimulation in vitro. A, Analysis of cell counts following serial stimulation in an MM1.S cell line in the presence or absence of 0.1 μmol/L Len. Data represent population doublings across 5 donors; error bars, SDs across 3 technical replicates. Linear mixed effects modeling indicated a significant effect for Len for each donor across time (P = 2.8 × 10−8). B–D, Analysis of bulk cytokine production 24 hours following serial stimulation replating at the indicated time points for 5 separate donors. Cytokine production was normalized to cell number at each reset to account for differences in cell replating density; error bars, SDs. Linear-mixed models indicated a significant effect for Len across donors and time points for IFNγ (P < 2.9 × 10−10), IL2 (P = 1.3 × 10−13), and TNFα (P = 1.2 × 10−9). *, P < 0.05 compared with vehicle for each donor.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Lenalidomide reduced functional exhaustion and altered surface phenotype of anti-BCMA CAR T cells. Cells were treated for 7 days on 50 μg BCMA-coated beads in the presence or absence of 1 μmol/L Len. A–D, Representative healthy donor–derived, freshly thawed anti-BCMA CAR T cells [vehicle (Veh), Len] or CAR T cells prestimulated with 7 days of BCMA bead stimulation and then cultured with RPMI-8226 cells to measure cytolytic activity (over 7 days; A) and cytokine production (24 hours; B–D). Percentage killing was normalized to anti-BCMA CAR T cells prestimulated on beads in the presence of vehicle. Prestimulated CAR T cells showed decreased cytolytic activity (P = 2.1 × 10−4) and cytokine production (P = 0.03 for IFNγ) compared with freshly thawed anti-BCMA CAR T cells. Len during the prestimulation period increased cytolytic function (P = 0.04). Significance was determined using t tests from linear regression coefficients. Three anti-BCMA CAR T donors (each column) were assessed for overall viability (E) and cell count and by flow cytometry (F) for median fluorescence intensity (MFI; CD25 and TIM3) or percentage positive PD-1 and LAG3 on the surface of T cell markers in CD4+ CAR+ and CD8+ CAR+ subsets (gated on live CD3+ cells). Values shown are percentage baseline (Veh) MFI, viability, or count. *, P < 0.05.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Anti-BCMA CAR T RNA-seq and ATAC-seq profiles were altered by lenalidomide after short- and long-term stimulation. A and C, Principal component analysis of expression (A; RNA-seq) and chromatin accessibility peaks (C; ATAC-seq). B and D, Volcano plots of differentially expressed genes (B) or peaks ± Len at 24 hours and 7 days (D). Directionality and significance of expression changes in selected, enriched biological pathways at 24 hours (E) and 7 days (F) in CAR T cells ± 1 μmol/L Len. G, RNA expression compared with chromatin accessibility changes for selected T cell loci. H, Top enriched motif predictions in ATAC-seq loci with increased accessibility along with their enrichment significance and prevalence at 7 days ± 1 μmol/L Len. FC, fold change; Ox, oxidative.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    In vivo efficacy of subcurative dose of anti-BCMA CAR T and blood anti-BCMA CAR T count was altered by lenalidomide. A, Two Len dosing regimens, concurrent (C) or delayed (D) daily dosing, were tested in a disseminated NSG mouse OPM-2 tumor model with a single, subcurative dose of anti-BCMA CAR T cells from 2 separate donors (8 mice per group). B–E, Tumor bioluminescent measurement (B and C) and animal survival (D and E). Error bars, SEM. Concurrent Len led to a significant decrease in tumor burden for donor 1 (P = 0.02) and increased survival (log-rank test) for donor 1 (P = 0.057) and donor 2 (P = 0.04) compared with vehicle (Veh)-treated animals injected with anti-BCMA CAR T alone. Linear mixed-effects models (accounting for repeated mouse measurements over time) were used to estimate treatment effects for the tumor burden analysis, and log-rank testing was used for significance testing for the survival analyses. F and G, Flow cytometric analysis of blood CAR T cells gated on CD45+ CD3+ CAR+. Error bars, SEM. Concurrent Len showed significantly increased CAR T expansion after 7 days in vivo (P = 7.3 × 10−6, t test). *, P < 0.05 for concurrent lenalidomide compared with vehicle control.

Additional Files

  • Figures
  • Supplementary Data

    • Supplementary Figure 1 - Supplementary Figure 1 shows information about the differential effects of lenalidomide with additional scfvs and the selected scfv at an additional E:T ratio with OPM-2 and RPMI-8226 cell lines
    • Supplementary Figure 2 - Supplementary Figure 2 shows the effect of lenalidomide on BCMA expression of the cell lines used in the experiments in this manuscript.
    • Supplementary Figure 3 - Supplementary Figure 3 shows the effect of lenalidomide on cytokine production by anti-BCMA CAR T cells stimulated with BCMA beads for 24 hours.
    • Supplementary Figure 4 - Supplementary Figure 4 shows the effects of lenalidomide on CD27, CCR7, CD45RA, and CAR positivity.
    • Supplementary Methods - Supplementary Methods and Figure Legends
    • Supplementary Table 1 - anti-BCMA CAR T amino acid sequence
PreviousNext
Back to top
Molecular Cancer Therapeutics: 18 (12)
December 2019
Volume 18, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Melissa Works, Neha Soni, Collin Hauskins, Catherine Sierra, Alex Baturevych, Jon C. Jones, Wendy Curtis, Patrick Carlson, Timothy G. Johnstone, David Kugler, Ronald J. Hause, Yue Jiang, Lindsey Wimberly, Christopher R. Clouser, Heidi K. Jessup, Blythe Sather, Ruth A. Salmon and Michael O. Ports
Mol Cancer Ther December 1 2019 (18) (12) 2246-2257; DOI: 10.1158/1535-7163.MCT-18-1146

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Melissa Works, Neha Soni, Collin Hauskins, Catherine Sierra, Alex Baturevych, Jon C. Jones, Wendy Curtis, Patrick Carlson, Timothy G. Johnstone, David Kugler, Ronald J. Hause, Yue Jiang, Lindsey Wimberly, Christopher R. Clouser, Heidi K. Jessup, Blythe Sather, Ruth A. Salmon and Michael O. Ports
Mol Cancer Ther December 1 2019 (18) (12) 2246-2257; DOI: 10.1158/1535-7163.MCT-18-1146
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Antineoplastic Effects of a Novel CDK2/9 Inhibitor CYC065
  • MTX-23, a Novel PROTAC That Degrades AR-V7 and AR-FL
  • Characterization of the IDO1 Inhibitor Linrodostat Mesylate
Show more Small Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement